The FDA approved an expanded indication for Enbrel (etanercept) to inhibit the structural damage of active arthritis in patients with psoriatic arthritis, reported Amgen Inc. and Wyeth Pharmaceuticals.
Expert Reflections: Impact of Dermatology Times
The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
Rituximab May Provide Alternative Treatment Option for Epidermolysis Bullosa Acquisita
The Cutaneous Connection: Enhancing Vitiligo Care With Nanette Silverberg, MD
First Study Reveals Covariate-Adjusted Effects of New Actinic Keratosis Therapies for Face and Scalp
Insights into Bimekizumab 2-Year Data for PsA, nr-asSpA, and AS